Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg
twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma.
Secondary objective: To assess the safety and tolerability of ciclesonide.